Literature DB >> 7504499

Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men.

W M Garraway1, E B Russell, R J Lee, G N Collins, G B McKelvie, M Hehir, A C Rogers, R J Simpson.   

Abstract

To assess the importance of benign prostatic hyperplasia on activities of daily living, a cross-sectional survey of 1627 men aged 40-79 years (representing a 65% response rate) registered with two health centres in central Scotland was carried out, using a urinary symptom questionnaire and uroflowmetry to identify men more likely to have benign prostatic hyperplasia. The condition was defined as a prostate gland of more than 20 g in the presence of symptoms of urinary dysfunction and/or a peak flow rate of less than 15 ml s-1, without evidence of malignancy. Transrectal ultrasonography was used to measure the volume (and by inference weight) of prostate glands. A total of 410 men satisfied the criteria for benign prostatic hyperplasia. Overall, 51% of men with benign prostatic hyperplasia reported interference with at least one of a number of selected activities of daily living as a result of urinary dysfunction, compared with 28% of men who did not have this condition. In 17% of men of working age (40-64 years) with benign prostatic hyperplasia, this interference occurred most or all of the time for at least one activity of daily living compared with only 3% of men in the same age group who did not have this condition. If the criteria of unmet need for treatment of benign prostatic hyperplasia constitutes interference by urinary dysfunction most or all of the time in at least one activity of daily living, then the findings of this survey suggest that a substantial number of middle aged and elderly men living in the United Kingdom may be in need of assessment and treatment for this condition.

Entities:  

Mesh:

Year:  1993        PMID: 7504499      PMCID: PMC1372554     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  12 in total

1.  Validation of a new quality of life questionnaire for benign prostatic hyperplasia.

Authors:  R S Epstein; P A Deverka; C G Chute; L Panser; J E Oesterling; M M Lieber; S Schwartz; D Patrick
Journal:  J Clin Epidemiol       Date:  1992-12       Impact factor: 6.437

2.  Some clinical aspects of uroflowmetry in elderly males. A population survey.

Authors:  K M Jensen; J B Jørgensen; P Mogensen; N E Bille-Brahe
Journal:  Scand J Urol Nephrol       Date:  1986

3.  Voiding patterns in men evaluated by a questionnaire survey.

Authors:  P Sommer; K K Nielsen; T Bauer; E S Kristensen; G G Hermann; K Steven; J Nordling
Journal:  Br J Urol       Date:  1990-02

4.  Urodynamics in prostatism. I. Prognostic value of uroflowmetry.

Authors:  K M Jensen; J B Jørgensen; P Mogensen
Journal:  Scand J Urol Nephrol       Date:  1988

5.  Symptom analysis and uroflowmetry 7 years after transurethral resection of the prostate.

Authors:  K T Nielsen; M M Christensen; P O Madsen; R C Bruskewitz
Journal:  J Urol       Date:  1989-11       Impact factor: 7.450

6.  A critical evaluation of the results of transurethral resection of the prostate.

Authors:  C P Chilton; R J Morgan; H R England; A M Paris; J P Blandy
Journal:  Br J Urol       Date:  1978-12

7.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study.

Authors:  A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

8.  Symptom status and quality of life following prostatectomy.

Authors:  F J Fowler; J E Wennberg; R P Timothy; M J Barry; A G Mulley; D Hanley
Journal:  JAMA       Date:  1988-05-27       Impact factor: 56.272

9.  The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study.

Authors:  R J Glynn; E W Campion; G R Bouchard; J E Silbert
Journal:  Am J Epidemiol       Date:  1985-01       Impact factor: 4.897

10.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

View more
  27 in total

Review 1.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older.

Authors:  Mohammad Reza Safarinejad
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

3.  Underdetection of clinical benign prostatic hyperplasia in a general medical practice.

Authors:  M F Collins; R H Friedman; A Ash; R Hall; M A Moskowitz
Journal:  J Gen Intern Med       Date:  1996-09       Impact factor: 5.128

4.  Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.

Authors:  Amyn Sayani; Afisi Ismaila; Anna Walker; John Posnett; Bruno Laroche; J Curtis Nickel; Zhen Su
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

5.  Perceptions of urinary symptoms and health-care-seeking behaviour amongst men aged 40-79 years.

Authors:  S Cunningham-Burley; H Allbutt; W M Garraway; A J Lee; E B Russell
Journal:  Br J Gen Pract       Date:  1996-06       Impact factor: 5.386

Review 6.  Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.

Authors:  Leonard S Marks
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 7.  Benign prostatic hyperplasia.

Authors:  R J Simpson
Journal:  Br J Gen Pract       Date:  1997-04       Impact factor: 5.386

8.  Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Zalmai Hakimi; Mike Herdman; Marco Pavesi; Nancy Devlin; Jameel Nazir; Chris Hoyle; Isaac A O Odeyemi
Journal:  Qual Life Res       Date:  2016-11-28       Impact factor: 4.147

9.  Risk of prostate cancer associated with benign prostate disease: a primary care case-control study.

Authors:  Brian S Buckley; Marie Carmela M Lapitan; Colin R Simpson; Aziz Sheikh
Journal:  Br J Gen Pract       Date:  2011-11       Impact factor: 5.386

10.  The impact of lower urinary tract symptoms on general health status and on the use of prostatectomy.

Authors:  D J Hunter; C M McKee; N A Black; C F Sanderson
Journal:  Qual Life Res       Date:  1995-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.